Last checked at 28 Apr 2017 07:00
Shield Therapeutics plc
("Shield" or the "Company" or the "Group")
2016 Annual Report and Accounts and 2017 AGM Notification
London, UK, 28 April 2017. Shield Therapeutics plc (LSE:STX), a specialty pharmaceutical Company focused on secondary care, gives notice that copies of its 2016 Annual Report and Accounts have been sent to shareholders. This document is available on the "Investors" section of the Company's website at www.shieldtherapeutics.com. Shield announced preliminary results for the year ended 31 December 2016 on 4 April 2017.
Further copies of the Annual Report will be available from the Company Secretary, Shield Therapeutics plc, Northern Design Centre, Baltic Business Quarter, Gateshead Quays, NE8 3DF.
Shield also announces that its Annual General Meeting will be held on 13 June 2017. The meeting will be held at Stephenson Harwood LLP, 1 Finsbury Circus, London EC2M 7SH, commencing at 2.00 pm. Notice of the Annual General Meeting has been sent to shareholders on Friday 28 April 2017.
- Ends -
For further information please contact:
Shield Therapeutics plc | +44 (0)207 186 8500 |
Carl Sterritt, Chief Executive Officer
| |
NOMAD Liberum Capital Limited Christopher Britton/Steve Pearce
| +44 (0)20 3100 2222 |
Financial PR Advisor Consilium Strategic Communications | +44 (0)203 709 5700 shieldtherapeutics@consilium-comms.com |
Mary-Jane Elliott/Matthew Neal/Lindsey Neville/Hendrik Thys |
About Shield Therapeutics plc
Shield Therapeutics is a specialty pharmaceutical company focused on the commercialisation and development of late-stage, hospital-focused pharmaceuticals which address areas of unmet medical need. Our clear purpose is to help our patients become people again, by enabling them to enjoy the things that make the difference in their everyday lives. The Group has a marketed product, Feraccru®, for the treatment of iron deficiency anaemia (IDA) in adult patients with inflammatory bowel disease (IBD) which has exclusive IP rights until the mid-2030's. In addition, the Group is developing PT20, a late-stage pharmaceutical for the treatment of systemic phosphate accumulation (hyperphosphatemia). Shield Therapeutics, headquartered in London, is listed on LSE's AIM under the ticker STX. For more information please visit www.shieldtherapeutics.com.